July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Control of mouse allergic conjunctivitis by resolvins
Author Affiliations & Notes
  • Satoshi Iwamoto
    Juntendo Univ School of Med, Chiyodaku, TOKYO, Japan
  • Takehiko Yokomizo
    Juntendo Univ School of Med, Chiyodaku, TOKYO, Japan
  • Akira Murakami
    Juntendo Univ School of Med, Chiyodaku, TOKYO, Japan
  • Akira Matsuda
    Juntendo Univ School of Med, Chiyodaku, TOKYO, Japan
  • Footnotes
    Commercial Relationships   Satoshi Iwamoto, None; Takehiko Yokomizo, None; Akira Murakami, None; Akira Matsuda, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5574. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Satoshi Iwamoto, Takehiko Yokomizo, Akira Murakami, Akira Matsuda; Control of mouse allergic conjunctivitis by resolvins. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5574.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are the ω3 polyunsaturated fatty acids that are found in fish oil. Resolvins are the metabolites of EPA and DHA. Previous reports showed that resolvins play anti-inflammatory and pro-resolving roles in vasculitis and asthma models in mice. In this study, we investigated the roles of DHA-derived resolvin D1 in allergic conjunctivitis using a mouse experimental allergic conjunctivitis model.

Methods : 10-12 weeks-old female BALB/c mice were used. Mice were sensitized and challenged for 4 days by ragweed pollen. Resolvin D1 (100 ng) was injected intraperitoneally before sensitization and before each challenge. 24 hours after the last challenge, conjunctival tissue was analyzed by Giemsa staining. Furthermore, serum total IgE and inflammatory cytokines in the conjunctiva were quantified by quantitative-PCR.

Results : The number of infiltrating eosinophil was reduced by resolvin D1 treatment. Expression of Il6 mRNA was attenuated by resolvin D1 treatment. On the other hand, concentration of total IgE and expression of Th2 (Il4, and Il13) cytokines in the conjunctiva were not affected by resolvin D1 treatment.

Conclusions : Resolvin D1 attenuated eosinophil infiltration in a mouse allergic conjunctivitis model. The effect of resolvin is not attributed to reduced total IgE and Th2 cytokine regulation. Resolvin might be a new therapeutic modality for allergic conjunctivitis.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.